PMV Pharmaceuticals (PMVP) Earnings Analysis
PMV Pharmaceuticals (PMVP) next reports earnings on 2026-08-06, consensus EPS -0.38 USD. Last quarter (2026-03-06) it beat with EPS -0.34 USD vs -0.4 USD est (+15%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -0.89.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PMVP next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.38 USD |
| Revenue estimate | n/a |
PMVP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-06 | -0.34 USD | -0.4 USD | +15% | Beat |
| 2025-11-12 | -0.4 USD | -0.4 USD | 0% | Beat |
| 2025-08-07 | -0.41 USD | -0.39 USD | -5.1% | Miss |
| 2025-05-09 | -0.34 USD | -0.37 USD | +8.1% | Beat |
| 2025-03-03 | -0.45 USD | -0.38 USD | -18.4% | Miss |
| 2024-08-08 | -0.02 USD | -0.34 USD | +94.1% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
PMVP valuation and analyst view
| Trailing P/E | -0.89 |
|---|---|
| Trailing EPS | -1.46899 USD |
| Price / book | 0.81 |
| Dividend yield | 0.00% |
| Market cap | 0.07B |
| Analyst consensus | Buy (4 buy / 0 hold / 0 sell) |
| Avg price target | 5 USD |
Related research pages
Frequently asked questions
When is PMV Pharmaceuticals (PMVP)'s next earnings date?
PMV Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.38 USD.
Did PMVP beat earnings last quarter?
In its 2026-03-06 report, PMVP posted EPS of -0.34 USD versus a -0.4 USD estimate — a beat of 15%.
What is PMVP's earnings track record?
Over the last 6 reported quarters with consensus data, PMVP beat estimates 4 times (67%).
What is PMVP's current P/E ratio and EPS?
PMVP trades at a trailing P/E of -0.89 on trailing EPS of -1.4689931700367844 USD.
What do analysts rate PMVP?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 5 USD.